Genetic code expansion (GCE) technology is a transformative tool in synthetic biology, enabling the site-specific incorporation of non-canonical amino acids (ncAAs) into proteins. This is achieved through engineered orthogonal aaRS/tRNA pairs, which introduce novel chemical functionalities beyond the canonical 20 amino acids. As a specialized biotech service provider, we leverage deep expertise in protein engineering and the advanced GCEngine platform to support the preclinical development of next-generation protein therapeutics. We offer customized development services for orthogonal translation systems and their application in creating novel biologics.
Traditional protein engineering primarily relies on the 20 canonical amino acids, which can limit the chemical diversity available for optimizing drug properties. GCE offers a pathway to move beyond this constraint by enabling the precise introduction of unique chemical moieties, such as bio-orthogonal handles (e.g., azides, alkynes), crosslinkers, or stabilizing groups, at defined sites within a protein. This technology facilitates the development of homogeneous, site-specifically modified biologics, such as novel enzyme therapies and long-acting hormones, opening new avenues to enhance their stability, potency, and pharmacokinetic profiles.
Fig.1 Site-specific incorporation of pTAF in target proteins. (Wang, Y., et al., 2023)
Integrating ncAAs into protein scaffolds provides a sophisticated strategy to address common pharmacological challenges. Through site-specific modification, researchers can pursue the following objectives:
Precision & Homogeneity
Targeting ncAA incorporation to a specific codon (e.g., the amber stop codon) facilitates the production of protein populations with defined, uniform modifications, which helps reduce heterogeneity compared to stochastic conjugation methods.
Expanded Chemical Diversity
The introduction of functional groups not found in nature (e.g., ketones, azides, alkynes) provides "anchor points" for specific, bio-orthogonal downstream chemistry on the protein scaffold, vastly expanding the chemical toolbox for protein engineering.
Enhanced Therapeutic Protein Properties
This includes conjugating PEG or other modules to improve serum half-life and bioavailability. Additionally, ncAAs can introduce stabilizing linkages, boosting thermal and proteolytic stability for manufacturing, storage, and in vivo performance.
Optimized Target Specificity
Engineering conditionally activated "caged" proteins or molecular switches that become active only in specific microenvironments (e.g., the tumor microenvironment) represents a promising strategy to minimize systemic toxicity.
Driven by our proprietary GCEngine platform, we deliver a seamless, end-to-end suite of services for ncAA-incorporated protein therapeutic development. From the initial identification of high-performance orthogonal aaRS/tRNA pairs to rigorous in vitro validation and complex in vivo application, our workflow is engineered to accelerate your candidate's journey from concept to preclinical proof-of-concept. Whether the goal is to improve a protein's stability or to create a highly potent enzyme-based therapeutic, our expertise in GCE-driven development can ensure that your molecular designs are translated into functional, high-purity therapeutic candidates.
Recognizing the unique challenges across therapeutic areas, our development services are tailored to specific disease contexts. This targeted approach ensures that the ncAA technology is applied strategically to solve relevant pathobiology-specific challenges.
Developing targeted protein toxins and cytokine-based therapies with enhanced tumor localization through bio-orthogonal tethering.
Autoimmune & Inflammatory Diseases
Creating precisely modulated signaling proteins that can selectively inhibit or activate immune pathways without systemic toxicity.
Metabolic & Rare Diseases
Creating long-acting therapeutic protein analogs or enzyme replacement therapies with optimized pharmacokinetic and functional properties.
By combining deep technical expertise with a commitment to scientific rigor, our key advantages include design flexibility, rigorous validation at every stage, and a proven track record of delivering functional, orthogonal systems. We aim to de-risk early-stage innovation and accelerate the path to proof of concept for novel biologic modalities. For detailed project consultations and to explore how our GCEngine platform can specifically advance your pipeline, please contact us.
All our services are exclusively intended for preclinical research purposes. They are not intended for diagnostic, therapeutic, or patient management applications.
A specialized platform advancing genetic code expansion through orthogonal tRNA/aaRS technologies, enabling precise ncAA incorporation for biotherapeutic development, synthetic biology, and diagnostics.